North American scientific gets OK.April brought good news and bad news for Chatsworth-based North American North American named after North America. North American blastomycosis see North American blastomycosis. North American cattle tick see boophilusannulatus. Scientific. the company reported on April 25 that it had received the thumbs up from the Food and Drug Administration to market its low-dose internal radiation breast cancer treatment This article or section recently underwent a major revision or rewrite and needs further review. You can help! The mainstay of breast cancer treatment is surgery when the tumor is localized, with possible adjuvant hormonal therapy (with tamoxifen or an aromatase . The company also announced that it was hoping to get approval for a similar, high-dose therapy product and be able to release both of the products in November. The technology is called brachytherapy, and uses radioactive seeds to treat prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. , and recently, breast cancer. Investors liked what they heard and the company's stock price went up 23 percent to $2.70 that day. On April 28, however, the company received notice from the Nasdaq Stock Market Nasdaq stock market The first electronic stock market listing over 5000 companies. The Nasdaq stock market comprises two separate markets, namely the Nasdaq National Market, which trades large, active securities and the Nasdaq Smallcap Market that trades emerging growth companies. that it did not meet the minimum $10 million stockholder's equity Stockholder's equity The residual claims that stockholders have against a firm's assets, calculated by subtracting all current liabilities and debt liabilities from total assets. requirement for continued listing on the exchange. The company requested a hearing before the Nasdaq Listing Qualifications Panel to ask for continued listing, but can't say what the outcome of the request will be. If its request is denied, the company may decide to seek listing on the National Capital Market. Staff reporter Jonathan D. Colburn can be reached at (818) 316-3124 or by email at jdcolburn@sfvbj.com. |
|
||||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion